Announcement on Using Partial Idle Raised Funds to Temporarily Supplement Current Capital
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
Announcement on Using Partial Idle Raised Funds to Temporarily Supplement Current Capital
Filed with SSE ·
6ix hasn’t read this filing yet.
Bio-Thera Solutions, Ltd. on 6ix
Earlier from Bio-Thera Solutions
- Announcement on Result of Shareholding Reduction by Shareholder
- Announcement on Return of Idle Raised Funds Temporarily Used to Supplement Current Capital
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT1308 Injection Combined with BAT4706 Injection and BAT8008 for Injection for Treatment of Advanced Solid Tumors
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (BAT5906)
- Announcement on the Change of Office Address and Contact Information of Investors
Later from Bio-Thera Solutions
- Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
- The European Commission (EC) Approves Bio-Thera Solutions' BAT2206 (USYMRO®, ustekinumab), a biosimilar referencing Stelara®
- Notice on Convening the 2nd Extraordinary General Meeting in 2025
- Announcement on Convening the Semi-annual Collective Performance Briefing for Innovative Drug Industry on SSE STAR Market 2025
- Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of Qletli (Adalimumab Solution for Injection) by UK MHRA
Follow Bio-Thera Solutions into a list and get an email when it puts out news.
Follow Bio-Thera Solutions